308 related articles for article (PubMed ID: 18398614)
1. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Morizane C; Okusaka T; Furuse J; Ishii H; Ueno H; Ikeda M; Nakachi K; Najima M; Ogura T; Suzuki E
Cancer Chemother Pharmacol; 2009 Jan; 63(2):313-9. PubMed ID: 18398614
[TBL] [Abstract][Full Text] [Related]
2. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Kawashima H; Itoh A; Ohno E; Nakamura M; Miyahara R; Ohmiya N; Hara K; Kanamori A; Itoh T; Taki T; Hirai T; Hashimoto S; Takeda K; Goto H; Hirooka Y
Cancer Chemother Pharmacol; 2011 Sep; 68(3):677-83. PubMed ID: 21132496
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Sudo K; Yamaguchi T; Nakamura K; Denda T; Hara T; Ishihara T; Yokosuka O
Cancer Chemother Pharmacol; 2011 Feb; 67(2):249-54. PubMed ID: 20352216
[TBL] [Abstract][Full Text] [Related]
4. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ioka T; Komatsu Y; Mizuno N; Tsuji A; Ohkawa S; Tanaka M; Iguchi H; Ishiguro A; Kitano M; Satoh T; Yamaguchi T; Takeda K; Kida M; Eguchi K; Ito T; Munakata M; Itoi T; Furuse J; Hamada C; Sakata Y
Br J Cancer; 2017 Feb; 116(4):464-471. PubMed ID: 28081543
[TBL] [Abstract][Full Text] [Related]
5. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
Todaka A; Fukutomi A; Boku N; Onozawa Y; Hironaka S; Yasui H; Yamazaki K; Taku K; Machida N; Sakamoto T; Tomita H
Jpn J Clin Oncol; 2010 Jun; 40(6):567-72. PubMed ID: 20189975
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Furuse J; Yamao K; Funakoshi A; Boku N; Ohkawa S; Yokosuka O; Tanaka K; Moriyasu F; Nakamori S; Sato T
Jpn J Clin Oncol; 2011 Aug; 41(8):953-8. PubMed ID: 21715364
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
[TBL] [Abstract][Full Text] [Related]
8. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Takahara N; Isayama H; Nakai Y; Ishigami H; Satoi S; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Yamaguchi H; Tada M; Kitayama J; Watanabe T; Koike K
Invest New Drugs; 2016 Oct; 34(5):636-42. PubMed ID: 27339809
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
[TBL] [Abstract][Full Text] [Related]
10. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Ioka T; Ueno M; Ueno H; Park JO; Chang HM; Sasahira N; Kanai M; Chung IJ; Ikeda M; Nakamori S; Mizuno N; Omuro Y; Yamaguchi T; Hara H; Sugimori K; Furuse J; Maguchi H; Furukawa M; Fukuzawa K; Kim JS; Yukisawa S; Takeuchi M; Okusaka T; Boku N; Hyodo I
Eur J Cancer; 2019 Jan; 106():78-88. PubMed ID: 30471651
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
[TBL] [Abstract][Full Text] [Related]
12. S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Kim MK; Lee KH; Jang BI; Kim TN; Eun JR; Bae SH; Ryoo HM; Lee SA; Hyun MS
Jpn J Clin Oncol; 2009 Jan; 39(1):49-53. PubMed ID: 19060295
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Song H; Han B; Park CK; Kim JH; Jeon JY; Kim IG; Kim HJ; Jung JY; Kim JH; Kwon JH; Jang G; Kim HY; Kim HS; Choi DR; Zang DY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):845-52. PubMed ID: 23978987
[TBL] [Abstract][Full Text] [Related]
15. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Oh DY; Cha Y; Choi IS; Yoon SY; Choi IK; Kim JH; Oh SC; Kim CD; Kim JS; Bang YJ; Kim YH
Cancer Chemother Pharmacol; 2010 Feb; 65(3):527-36. PubMed ID: 19578850
[TBL] [Abstract][Full Text] [Related]
16. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study.
Togawa A; Yoshitomi H; Ito H; Kimura F; Shimizu H; Ohtsuka M; Yoshidome H; Kato A; Sawada S; Miyazaki M
Int J Clin Oncol; 2007 Aug; 12(4):268-73. PubMed ID: 17701005
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
Cheng YJ; Meng CT; Shao YJ; Li NN; Zhou N; Yan XY; Gao X; Zhou JF; Bai CM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):562-567. PubMed ID: 28877836
[TBL] [Abstract][Full Text] [Related]
18. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3).
Go SI; Lee SC; Bae WK; Zang DY; Lee HW; Jang JS; Ji JH; Kim JH; Park S; Sym SJ; Yang Y; Jeon SY; Hwang IG; Oh SY; Kang JH
Eur J Cancer; 2021 Nov; 157():21-30. PubMed ID: 34464782
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Sasaki T; Isayama H; Nakai Y; Mizuno S; Yamamoto K; Yagioka H; Yashima Y; Kawakubo K; Kogure H; Togawa O; Matsubara S; Ito Y; Sasahira N; Hirano K; Tsujino T; Toda N; Tada M; Omata M; Koike K
Invest New Drugs; 2012 Apr; 30(2):708-13. PubMed ID: 20924641
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
